SynthesisClinical journal of the American Society of Nephrology : CJASN2009
Rituximab therapy for membranous nephropathy: a systematic review.
Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.The Cochrane database of systematic reviews · 2021Pooled it
- Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.Journal of the American Society of Nephrology : JASN · 2017Trial
- Rituximab in idiopathic membranous nephropathy.Journal of the American Society of Nephrology : JASN · 2012Trial
- Rituximab for the treatment of membranous nephropathy in a patient with ankylosing spondylitis: a case report.Frontiers in medicine · 2026Article
- Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study.Frontiers in molecular biosciences · 2026Article
- Rituximab treatment in non-lupus full-house nephropathy: A case report.SAGE open medical case reports · 2025Article
- Ten tips on immunosuppression in primary membranous nephropathy.Clinical kidney journal · 2024Review
- Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.The Korean journal of internal medicine · 2022Review
- Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.Journal of nephrology · 2021Article
- Idiopathic Membranous Nephropathy and Treatment Related Complications.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Article
- Rituximab in kidney disease and transplant.Animal models and experimental medicine · 2019Review
- Immune-Monitoring Disease Activity in Primary Membranous Nephropathy.Frontiers in medicine · 2019Review
- The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation.Clinical kidney journal · 2018Article
- Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy.Kidney international reports · 2018Article
- Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy.Clinical kidney journal · 2018Article
- Treatment of membranous nephropathy: time for a paradigm shift.Nature reviews. Nephrology · 2017Review
- Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.Clinical kidney journal · 2017Article
- Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.BMC nephrology · 2017Article
- Review
- Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.Internal medicine (Tokyo, Japan) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesThe treatment of membranous nephropathy (MN) remains controversial. Rituximab, which selectively targets B cells, has emerged as a possible alternative treatment option with limited toxicity. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The available data on rituximab therapy for MN were reviewed using the MEDLINE database (inception to August 1, 2008), Google Scholar, and selected reference lists. English-language studies investigating the use of rituximab in idiopathic and secondary MN, in native and transplanted kidneys, were included. Study design, subject number, clinical characteristics (diagnosis, previous and concomitant treatment courses, baseline proteinuria, baseline renal function), rituximab protocol, follow-up period, achievement of complete or partial remission, changes in proteinuria and renal function, and adverse effects of therapy were extracted.
resultsTwenty-one articles were included for review; all were either case reports or case series without controls. More than half of the published cases (50 of 85) came from one center where rituximab was used as primary immunosuppression for idiopathic MN. The available data suggest that rituximab, dosed either as 375 mg/m(2) once weekly for 4 wk or as 1 g on days 1 and 15, achieves a 15 to 20% rate of complete remission and a 35 to 40% rate of partial remission. The drug was well tolerated with minimal adverse events.
conclusionsAlthough rituximab may prove to be a better treatment option for MN than alkylating agents or calcineurin inhibitors, the current literature only supports using the drug in research protocols. Whether, when, how, and why to use rituximab in MN remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.